Abliva AB is a Swedish company which is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.
Lund, SE-223 81, Sweden